Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea

This study has been completed.
Salix Pharmaceuticals
The University of Texas Health Science Center, Houston
Information provided by:
DuPont, Hurbert L., MD
ClinicalTrials.gov Identifier:
First received: December 7, 2004
Last updated: May 8, 2006
Last verified: December 2004

December 7, 2004
May 8, 2006
June 2003
Not Provided
Occurrence of diarrhea, defined as passage of >2 unformed stools/24 hr plus one or more signs or symptoms of enteric infection
Same as current
Complete list of historical versions of study NCT00098384 on ClinicalTrials.gov Archive Site
  • Occurrence of mild diarrhea (1 or 2 unformed stools/24 hr plus a sign or symptom)
  • Treatment failure (not well in five days)
  • Occurrence of moderate to severe abdominal pain/cramps or intestinal gas related symptoms
Same as current
Not Provided
Not Provided
Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea
A Randomized, Double-Blind, Single Center, Comparative Dose Ranging Study of Rifaximin Vs. Placebo in the Prevention of Travelers' Diarrhea Due to Enteropathogenic Bacteria

The purpose of this study is to evaluate the effectiveness of poorly absorbed rifaximin in the prevention of travelers' diarrhea among U.S. college students in Mexico for five weeks.

This is an investigator-initiated proposal wherein 220 male and female subjects >17 years of age from industrialized regions were randomized to receive a poorly absorbed antibiotic, rifaximin, in one of three doses at mealtime (when they are exposed to diarrhea-causing bacteria), 200 mg once a day, 200 mg twice a day or 200 mg three times a day versus a placebo starting on arrival (within the first 72 hours) to Mexico and continuing for two weeks with diaries of symptoms recorded for three weeks. Adverse events in the subjects were followed for five weeks. If mild diarrhea (1 or 2 unformed stools/24 hours plus an enteric symptom) or diarrheal illness (>2 unformed stools/24 hours plus an enteric symptom) developed, subjects provided a stool sample to determine cause of illness. Forty subjects provided stool samples after 7 days and 14 days treatment to see if their intestinal bacterial flora had developed resistance to rifaximin and to see the level of drug achieved. Stool samples from these forty subjects were studied for enteric pathogens to look for asymptomatic infection during the period of prophylaxis. The stool samples collected were initially processed in our enteric laboratories in Guadalajara, Mexico. Specialized tests such as studies of toxigenicity for enterotoxigenic E. coli and enteroadherence for enteroaggregative E. coli were done in Houston.

Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Drug: rifaximin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
September 2003
Not Provided

Inclusion Criteria:

  • An Investigational Review Board approved, written informed consent is appropriately witnessed, signed and dated prior to any study-related activities
  • Male or female subjects 18 years of age or older
  • Able to read and understand English
  • Enrolled and started on prophylaxis within 72 hours of arrival in Mexico
  • If the subject is female, only women with non-childbearing potential or those who are not pregnant will be eligible. Urine pregnancy tests will be performed on those women who question their pregnancy status. Women on the study are required to employ a reliable method of contraception while taking medication. Forms of acceptable contraception include:

    • Double barrier method of contraception.
    • Oral birth control pills for at least two cycles before enrollment and continuing during therapy – subjects will be told they should use a barrier contraception method during the study as well.
    • Norplant inserted at least one month before enrollment.
    • An intrauterine device inserted by a qualified clinician.
    • Medroxyprogesterone acetate for a minimum of one month before study and administered for one month following study completion.
    • An approved birth control patch for at least two cycles before enrollment and continuing during therapy. OR
    • Complete abstinence from intercourse for the two weeks of medication.

Exclusion Criteria:

  • Acute diarrhea (criteria for travelers’ diarrhea above) within the past week
  • Diarrhea developing within 24 hours of study enrollment
  • In Mexico for more than 72 hours
  • Receipt of one of the following classes of drugs: fluoroquinolone (any drug in class), macrolide or azalide or trimethoprim-sulfamethoxazole within the past week or during the three week study
  • Receipt of other medication to decrease the occurrence of diarrhea (e.g. bismuth subsalicylate or lactobacillus preparations)
  • For females, pregnancy or breast feeding during the three week study
  • Receipt of antidiarrheal medication (loperamide, bismuth subsalicylate, kaopectate) within 24 hours of enrollment
  • Hypersensitivity to rifaximin
  • Unstable medical condition including chronic renal failure and insulin dependent diabetes.
18 Years and older
Contact information is only displayed when the study is recruiting subjects
PR 03
Not Provided
Not Provided
DuPont, Hurbert L., MD
  • Salix Pharmaceuticals
  • The University of Texas Health Science Center, Houston
Not Provided
DuPont, Hurbert L., MD
December 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP